Novel processes to obtain pneumococcal surface proteins for vaccines

IF 3.9 3区 生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Viviane Maimoni Gonçalves
{"title":"Novel processes to obtain pneumococcal surface proteins for vaccines","authors":"Viviane Maimoni Gonçalves","doi":"10.1007/s00253-025-13440-2","DOIUrl":null,"url":null,"abstract":"<p>Current pneumococcal vaccines are based on the protection offered by capsular polysaccharides from only a few from &gt; 100 serotypes; therefore, serotype-independent vaccines composed of pneumococcal surface proteins are being developed. Despite the immense number of publications on the discovery, characterization, and evaluation of new pneumococcal vaccine candidates, there are very few that describe the bioprocess development, which is an essential step to generate material for pre-clinical and clinical tests, to obtain enough protein amount for physical–chemical, biochemical, and biological characterization, and to understand critical product and process attributes. Here, aspects of production and purification processes of pneumococcal surface proteins are reviewed, the most common bioreactor cultivation strategies are discussed, and important features of the purification process are explored to bring new insights about the correlation between protein structure and chromatography. The process development oriented to an industrial scale is an essential step for the success of novel protein-based pneumococcal vaccines and can preclude problems that could be hardly identified at flask scale production. Moreover, the early bioprocess development should favor a smooth scale-up and transfer of the process to GMP facilities for future production of new pneumococcal vaccines.</p><p>• <i>Early bioprocess development is crucial to advancing pneumococcal protein vaccines.</i></p><p>• <i>Bioreactor cultivation can help to identify possible process bottlenecks.</i></p><p>• <i>Structural features of similar proteins can orient purification process development.</i></p>","PeriodicalId":8342,"journal":{"name":"Applied Microbiology and Biotechnology","volume":"109 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00253-025-13440-2.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Microbiology and Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://link.springer.com/article/10.1007/s00253-025-13440-2","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Current pneumococcal vaccines are based on the protection offered by capsular polysaccharides from only a few from > 100 serotypes; therefore, serotype-independent vaccines composed of pneumococcal surface proteins are being developed. Despite the immense number of publications on the discovery, characterization, and evaluation of new pneumococcal vaccine candidates, there are very few that describe the bioprocess development, which is an essential step to generate material for pre-clinical and clinical tests, to obtain enough protein amount for physical–chemical, biochemical, and biological characterization, and to understand critical product and process attributes. Here, aspects of production and purification processes of pneumococcal surface proteins are reviewed, the most common bioreactor cultivation strategies are discussed, and important features of the purification process are explored to bring new insights about the correlation between protein structure and chromatography. The process development oriented to an industrial scale is an essential step for the success of novel protein-based pneumococcal vaccines and can preclude problems that could be hardly identified at flask scale production. Moreover, the early bioprocess development should favor a smooth scale-up and transfer of the process to GMP facilities for future production of new pneumococcal vaccines.

• Early bioprocess development is crucial to advancing pneumococcal protein vaccines.

• Bioreactor cultivation can help to identify possible process bottlenecks.

• Structural features of similar proteins can orient purification process development.

获得肺炎球菌疫苗表面蛋白的新工艺
目前的肺炎球菌疫苗是基于来自100种血清型的荚膜多糖提供的保护;因此,正在开发由肺炎球菌表面蛋白组成的血清型独立疫苗。尽管有大量关于发现、表征和评估新的肺炎球菌候选疫苗的出版物,但很少有描述生物工艺开发的出版物,这是为临床前和临床试验生成材料的必要步骤,以获得足够的蛋白质量进行物理化学、生化和生物学表征,并了解关键的产品和工艺属性。本文综述了肺炎球菌表面蛋白的生产和纯化过程,讨论了最常见的生物反应器培养策略,并探讨了纯化过程的重要特征,为蛋白质结构与色谱之间的关系带来了新的见解。面向工业规模的工艺开发是新型基于蛋白质的肺炎球菌疫苗取得成功的重要一步,可以排除在烧瓶规模生产中难以发现的问题。此外,早期生物工艺开发应有利于顺利扩大规模并将该工艺转移到GMP设施,以便将来生产新的肺炎球菌疫苗。•早期生物工艺开发对推进肺炎球菌蛋白疫苗至关重要。•生物反应器培养可以帮助识别可能的工艺瓶颈。•相似蛋白的结构特征可以指导纯化工艺的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Applied Microbiology and Biotechnology
Applied Microbiology and Biotechnology 工程技术-生物工程与应用微生物
CiteScore
10.00
自引率
4.00%
发文量
535
审稿时长
2 months
期刊介绍: Applied Microbiology and Biotechnology focusses on prokaryotic or eukaryotic cells, relevant enzymes and proteins; applied genetics and molecular biotechnology; genomics and proteomics; applied microbial and cell physiology; environmental biotechnology; process and products and more. The journal welcomes full-length papers and mini-reviews of new and emerging products, processes and technologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信